The legacy of Viagra and its originator, copyright, presents a complex picture for cautious investors. While the revolutionary drug initially generated enormous earnings, its protection has ended, leading to rival versions flooding the market . This erosion in cost presents a significant hurdle for copyright and any fund considering a heavy stake i